What is Biohaven Pharmaceuticals's contact information?

Biohaven Pharmaceuticals's contact information: +12034040410.

How many employees does Biohaven Pharmaceuticals have?

Biohaven Pharmaceuticals has 300 employees.

What industry does Biohaven Pharmaceuticals belong to?

Biohaven Pharmaceuticals is in the industry of: Research, Pharmaceuticals, Biotechnology, Healthcare.

What are Biohaven Pharmaceuticals's official social media profiles?

Biohaven Pharmaceuticals Linkedin Page Biohaven Pharmaceuticals Facebook Page Biohaven Pharmaceuticals Instagram Page Biohaven Pharmaceuticals Twitter Page

What tech stack does Biohaven Pharmaceuticals use?

Some of the popular technologies that Biohaven Pharmaceuticals uses are: AccessiBe, Google Analytics, Leadfeeder, WordPress.

What are Biohaven Pharmaceuticals's office addresses?

Biohaven Pharmaceuticals has 2 known office addresses: 215 Church Street New Haven, CT 06510, US 215 Church Street, New Haven, Ct 06510, Us.

What is Biohaven Pharmaceuticals's estimated annual revenue?

Biohaven Pharmaceuticals's revenue is $50,000,000

What is Biohaven Pharmaceuticals's open headcount?

Biohaven Pharmaceuticals has no job postings yet.

What is the number of ad campaigns for Biohaven Pharmaceuticals?

Biohaven Pharmaceuticals has no advertisements yet.

What is the number of recent news articles about Biohaven Pharmaceuticals?

Biohaven Pharmaceuticals has 3 news articles.

Biohaven Pharmaceuticals - Pubrio Company Profile & Intent

Biohaven Pharmaceuticals

United States · Research

Research

Pharmaceuticals

Biotechnology

Healthcare

Biohaven is a Connecticut-based pharmaceutical company that researches and develops novel drugs for the treatment of neurological and neuropsychiatric diseases.

Company Insights

docdocdoc.co.kr · launches · 2025-12-19

Open news

AimD Bio's strategy: Clinical trial leadership in ADC competition

AimD Bio focuses on clinical trial leadership in ADC competition, emphasizing asset-centric strategy, patient-derived cell platforms, and global partnerships for sustainable growth and clinical success.

Sk Plasma

Samsung Biologics

Biohaven Pharmaceuticals

Boehringer Ingelheim

docdocdoc.co.kr · goes_public · 2025-11-19

Open news

AimD Bio faces clinical trial challenge after tech transfers

AimD Bio prepares for IPO with $3 billion in tech transfers, but faces challenges in proving clinical efficacy. The company aims for a $700 million valuation, focusing on less competitive ADC targets like FGFR3 and KRAS.

Biohaven Pharmaceuticals

Boehringer Ingelheim

ad-hoc-news.de · partners_with · 2025-01-13

Open news

Merus and Biohaven collaborate on bispecific ADC programs

Merus and Biohaven partner to develop three novel bispecific antibody-drug conjugates using Merus' Biclonics platform and Biohaven's ADC technologies.

Merus N.V.

Biohaven Pharmaceuticals

khgames.co.kr · is_developing · one week ago

Open news

Bitcoin option investors bet on downside despite price rise

Bitcoin ETF and crypto-holding firms are buying put options to hedge against potential price drops below $60,000, despite recent price increases.

Coindesk

Deribit

khgames.co.kr · is_developing · one week ago

Open news

Bitcoin's 'Death Cross' Appears: Future Trends?

Bitcoin chart shows 'death cross' pattern, historically preceding major price drops. Despite this, ETFs see $1 billion inflow and long-term investors continue accumulating.

Coindesk

Upbit Singapore

coinreaders.com · launches · one week ago

Open news

JPMorgan: Crypto Market Structure Act likely to pass mid-year

JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.

Coindesk

J.P. Morgan

Get full access to view complete information

1 - 3 of 3

Frequently Asked Questions Regarding Biohaven Pharmaceuticals

Company Overview

2022

Founded

Research

Industry

United States

Location

1,712,259

Ranking

300 employees

Size

Similar Companies

Get full access to view complete information